Publications by authors named "Sankar Navaneethan"

Claim this Profile
E
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.
Anastasia Uster, Nihar Desai, Sankar D Navaneethan, Egon Pfarr, Anna Rita Mazo

Clin Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incident Pulmonary Hypertension and Its Risk Factors in CKD.
Marcelle Tuttle, Hocine Tighiouart, Tatsufumi Oka, Wendy McCallum, Nicholas S Hill, Sankar Navaneethan

Clin J Am Soc Nephrol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Assessment in Cardiovascular-Kidney-Metabolic Syndrome: An Opportunity to Individualize Evidence-Based Therapy in CKD.
L Parker Gregg, Biykem Bozkurt, Sankar D Navaneethan

Clin J Am Soc Nephrol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time for Broader Adoption of SGLT2 Inhibitors in Clinical Practice?
L Parker Gregg, Biykem Bozkurt, Sankar D Navaneethan

JAMA· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.
David C Wheeler, Kevin M Pantalone, Lixin Guo, Nihar R Desai, Ricardo Correa-Rotter, Sankar D Navaneethan

Clin Kidney J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Function Decline in Incident Heart Failure Is a Surrogate Marker for Kidney Failure and Mortality.
Carl P Walther, Katherine R Tuttle, Sankar D Navaneethan

JACC Heart Fail· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Function Trajectories With Mechanical Circulatory Support.
Carl P Walther, Harveen K Lamba, Ajith P Nair, Andrew B Civitello, Nandan K Mondal, Sankar D Navaneethan

Kidney Int Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Susan L Furth, Helen M Colhoun, Mehmet Kanbay, Aleksandra Kukla, Lee-Ling Lim, Sankar D Navaneethan

Kidney Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperkalemia risk of finerenone versus spironolactone in CKD patients with type 2 diabetes.
Abiodun Idowu, Kevin Bryan Lo, Olayinka Adebolu, Michael Hamilton, Peter Abdelmaseeh, Sankar D Navaneethan

Nephrol Dial Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in treatment options for kidney disease.
Kripa Kohli, Sankar D Navaneethan

Curr Opin Nephrol Hypertens· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of SGLT2 inhibitors on glomerular filtration in type 1 diabetes.
Michael W Holliday, Sankar D Navaneethan

J Clin Endocrinol Metab· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation.
Carl P Walther, L Parker Gregg, Sankar D Navaneethan

Am J Kidney Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.
Sankar D Navaneethan, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing

Kidney Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Energy Diets: Potential Treatment Option for Patients With Obesity and Early-Stage CKD?
Elizabeth C Lorenz, Sankar D Navaneethan

Kidney Int Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.
Seth S Martin, Aaron W Aday, Zaid I Almarzooq, Cheryl A M Anderson, Pankaj Arora, Sankar D Navaneethan

Circulation· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.
Ian H de Boer, M Luiza Caramori, Juliana C N Chan, Hiddo J L Heerspink, Kamlesh Khunti, Sankar D Navaneethan

Kidney Int· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.
Sankar D Navaneethan, Nisha Bansal, Kerri L Cavanaugh, Alexander Chang, Susan Crowley

Am J Kidney Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD.
L Parker Gregg, Peter A Richardson, Vijay Nambi, Laura A Petersen, Michael E Matheny, Sankar D Navaneethan

J Am Soc Nephrol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases.
T Alp Ikizler, Holly J Kramer, Srinivasan Beddhu, Alex R Chang, Allon N Friedman, Sankar Dass Navaneethan

J Am Soc Nephrol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.
Susanne B Nicholas, Ricardo Correa-Rotter, Nihar R Desai, Lixin Guo, Sankar D Navaneethan

J Nephrol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease.
Marcelle Tuttle, Mark J Sarnak, Sankar D Navaneethan

Curr Opin Nephrol Hypertens· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators.
Julio A Lamprea-Montealegre, Abigail Shapiro, Natalie A B Bontrager, Dena E Rifkin, Simerjot K Jassal, Sankar D Navaneethan

Kidney Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States.
Abdul Mannan Khan Minhas, Roy O Mathew, Laurence S Sperling, Vijay Nambi, Salim S Virani, Sankar D Navaneethan

J Am Coll Cardiol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Patrizia Natale, Suetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, Giovanni Fm Strippoli

Cochrane Database Syst Rev· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Function Trajectories and Right Heart Failure Following LVAD Implantation.
Carl P Walther, Andrew B Civitello, Harveen K Lamba, Nandan K Mondal, Sankar D Navaneethan

J Am Heart Assoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis